Literature DB >> 9657262

LAG-3 does not define a specific mode of natural killing in human.

B Huard1, M Tournier, F Triebel.   

Abstract

LAG-3 is a gene localized on the band p13 of human chromosome 12, close to the NK gene complex (NKC), expressed on activated NK cells and encoding a receptor for MHC class II molecules. Recently, LAG-3 has been proposed to define a specific mode of natural killing in mice. The putative role of LAG-3 on human natural killer cytotoxicity has been examined with specific monoclonal antibodies and a recombinant soluble form of LAG-3. Neither the antibodies, which are able to block the interaction with the ligand, nor the recombinant product, which has retained its binding capacity for MHC class II, had an effect on the natural killing of various target cells. Furthermore, in redirected killing assays, none of these antibodies were able to modulate either positively or negatively the cytotoxicity. Taken together, these data show that LAG-3 has no transducing activity involved in NK cytotoxicity, ruling out the existence of a specific mode of natural killing defined by this molecule in humans.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9657262     DOI: 10.1016/s0165-2478(97)00170-3

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  29 in total

Review 1.  Stromal-cell regulation of natural killer cell differentiation.

Authors:  Claude Roth; Carla Rothlin; Sylvain Riou; David H Raulet; Greg Lemke
Journal:  J Mol Med (Berl)       Date:  2007-04-11       Impact factor: 4.599

Review 2.  Killers 2.0: NK cell therapies at the forefront of cancer control.

Authors:  Jonathan J Hodgins; Sarwat T Khan; Maria M Park; Rebecca C Auer; Michele Ardolino
Journal:  J Clin Invest       Date:  2019-09-03       Impact factor: 14.808

Review 3.  LAG-3 in Cancer Immunotherapy.

Authors:  Monica V Goldberg; Charles G Drake
Journal:  Curr Top Microbiol Immunol       Date:  2011       Impact factor: 4.291

Review 4.  Exploring the NK cell platform for cancer immunotherapy.

Authors:  Jacob A Myers; Jeffrey S Miller
Journal:  Nat Rev Clin Oncol       Date:  2020-09-15       Impact factor: 66.675

Review 5.  The Potential Role of Inhibitory Receptors in the Treatment of Psoriasis.

Authors:  Neha Shah; Sabina Sandigursky; Adam Mor
Journal:  Bull Hosp Jt Dis (2013)       Date:  2017-05

6.  LAG-3 Blockade with Relatlimab (BMS-986016) Restores Anti-Leukemic Responses in Chronic Lymphocytic Leukemia.

Authors:  Christian Sordo-Bahamonde; Seila Lorenzo-Herrero; Ana P González-Rodríguez; Ángel R Payer; Esther González-García; Alejandro López-Soto; Segundo Gonzalez
Journal:  Cancers (Basel)       Date:  2021-04-27       Impact factor: 6.639

Review 7.  Understanding LAG-3 Signaling.

Authors:  Luisa Chocarro; Ester Blanco; Miren Zuazo; Hugo Arasanz; Ana Bocanegra; Leticia Fernández-Rubio; Pilar Morente; Gonzalo Fernández-Hinojal; Miriam Echaide; Maider Garnica; Pablo Ramos; Ruth Vera; Grazyna Kochan; David Escors
Journal:  Int J Mol Sci       Date:  2021-05-17       Impact factor: 5.923

Review 8.  Control of NK Cell Activation by Immune Checkpoint Molecules.

Authors:  Asma Beldi-Ferchiou; Sophie Caillat-Zucman
Journal:  Int J Mol Sci       Date:  2017-10-12       Impact factor: 5.923

Review 9.  Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells.

Authors:  Nayoung Kim; Hun Sik Kim
Journal:  Front Immunol       Date:  2018-09-10       Impact factor: 7.561

Review 10.  Detection of Immune Checkpoint Receptors - A Current Challenge in Clinical Flow Cytometry.

Authors:  Benjamin Shibru; Katharina Fey; Stephan Fricke; André-René Blaudszun; Friederike Fürst; Max Weise; Sabine Seiffert; Maria Katharina Weyh; Ulrike Köhl; Ulrich Sack; Andreas Boldt
Journal:  Front Immunol       Date:  2021-07-01       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.